RCPT up +0.70% percent right now. $RCPT High is at 112.17

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
RCPT up +0.70% percent right now. $RCPT High is at 112.17 and the Low 108.25 with current volume of 263,421.

Recent News posted below.

RCPT Receptos Inc Recent Headline News

Receptos to Present at Credit Suisse Healthcare Conference
GlobeNewswire - Thu Nov 06, 3:03PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Credit Suisse Healthcare Conference at The Biltmore Hotel in Phoenix, Arizona. The presentation is scheduled for Wednesday, November 12 at 8:30am. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 109.80 (+0.56)

Receptos' (RCPT) CEO Faheem Hasnain on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 11:46AM CST

RCPT: 109.80 (+0.56)

Receptos posts 3Q loss
Automated Insights - Tue Nov 04, 7:19AM CST
SAN DIEGO (AP) _ Receptos Inc. (RCPT) on Tuesday reported a loss of $32.2 million in its third quarter.
RCPT: 109.80 (+0.56)

Receptos misses by $0.23, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 6:04AM CST

RCPT: 109.80 (+0.56)

Receptos Provides Development Updates and Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
- Recent positive Phase 2 induction results for TOUCHSTONE trial of RPC1063 in ulcerative colitis (UC) support initiation of broad program in inflammatory bowel disease -
RCPT: 109.80 (+0.56)

Receptos to Present at Nomura BioPharma Conference
GlobeNewswire - Mon Nov 03, 3:01PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Nomura BioPharma Conference at the Mandarin Oriental Hotel in Boston. The presentation is scheduled for Thursday, November 6 at 2:15pm Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 109.80 (+0.56)

Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 44.06 (+0.69), WMGI: 27.93 (-0.02), CFN: 57.42 (+0.14), UTHR: 125.12 (+0.91), RCPT: 109.80 (+0.56), WMGIZ: 4.40 (+0.09)

Receptos to Hold Third Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the third quarter ended September 30, 2014 on Tuesday, November 4 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time (5:00 a.m. Pacific time).
RCPT: 109.80 (+0.56)

Receptos (RCPT) Worth Watching: Stock Moves Up 41.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:39AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as its shares rose over 41% on the day.
LCI: 52.01 (+1.84), PTLA: 27.47 (+0.08), RCPT: 109.80 (+0.56), IG: 9.59 (+0.14)

Nasdaq stocks posting largest percentage increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
VDSI: 28.24 (+1.61), ECHO: 27.93 (+0.60), LAYN: 7.60 (+0.08), NVAX: 5.17 (+0.22), SCYX: 9.50 (+0.50), RCPT: 109.80 (+0.56), TRNX: 26.06 (+0.56), IDTI: 18.11 (+0.38), SANM: 25.33 (-0.27)

Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.33 (-0.06), KSS: 56.60 (-0.62), MU: 33.00 (-0.01), PFE: 30.25 (+0.33), HAL: 53.57 (-0.29), AMGN: 163.03 (+2.78), NQ: 7.55 (+0.37), RGC: 22.50 (+0.35), MS: 35.75 (+0.09), MSG: 74.82 (-0.33), NVAX: 5.17 (+0.22), CQB: 14.44 (+0.01), SRPT: 16.02 (-0.10), RCPT: 109.80 (+0.56), TWTR: 39.67 (-0.64), PTIE: 1.68 (-0.03)

Health Care Stocks On The Rise With Help From 3 Stocks
at The Street - Tue Oct 28, 12:04PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
AMGN: 163.03 (+2.78), RCPT: 109.80 (+0.56), NVS: 92.61 (+0.85)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:46AM CDT

RGSE: 0.85 (-0.08), AMKR: 6.33 (-0.06), VTAE: 17.23 (+2.79), ASTI: 1.89 (-0.09), CLF: 11.23 (+0.06), LMNX: 18.22 (+0.18), IDTI: 18.11 (+0.38), HNR: 3.02 (-0.15), VDSI: 28.24 (+1.61), DCO: 23.68 (-0.36), MDCO: 24.40 (-0.19), SCYX: 9.50 (+0.50), VGGL: 1.60 (+0.02), RCPT: 109.80 (+0.56), IBIO: 1.23 (+0.07), SNY: 46.35 (+0.66), TWTR: 39.67 (-0.64), DPW: 1.63 (-0.04), MERU: 4.03 (+0.02), SANM: 25.33 (-0.27)

Receptos Soars After Lead Drug Racks Up Another Win
at Investor's Business Daily - Tue Oct 28, 10:46AM CDT
Receptos (RCPT) stock jumped more than 47% to a new high above 99 in morning trading on the stock market today, and the company got multiple price-target increases after its bowel-disease drug succeeded in a midstage trial. Receptos announced late...
JNJ: 108.89 (+0.69), RCPT: 109.80 (+0.56), ABBV: 63.76 (+2.26)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 8:13AM CDT

KSS: 56.60 (-0.62), FRO: 1.38 (-0.02), ASTI: 1.89 (-0.09), TRNX: 26.06 (+0.56), CVLT: 48.21 (+0.15), UBS: 17.13 (+0.07), BWLD: 158.94 (+1.43), HASI: 13.68 (+0.05), COH: 33.81 (+0.15), VDSI: 28.24 (+1.61), MSG: 74.82 (-0.33), NVO: 43.31 (-0.38), ACI: 2.51 (-0.35), RCPT: 109.80 (+0.56), TWTR: 39.67 (-0.64), SNY: 46.35 (+0.66), FOLD: 6.20 (+0.48), NE: 21.03 (-0.80)

Stock Futures Positive, Steady; Vasco Rockets, Twitter Fades
at Investor's Business Daily - Tue Oct 28, 8:01AM CDT
Stock futures rolled up moderate gains ahead of Tuesday's open, as investors geared up for a session with many moving parts. Dow futures were steady, trading 73.1 points above fair market value. Nasdaq 100 futures were up a strong 19.4 points, and...
WHR: 174.04 (-1.77), VDSI: 28.24 (+1.61), RCPT: 109.80 (+0.56), BP: 41.90 (-0.16), TWTR: 39.67 (-0.64), AET: 83.86 (+1.57)

Receptos up premarket on UC trial results
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 7:09AM CDT

RCPT: 109.80 (+0.56)

RECEPTOS
at Investor's Business Daily - Mon Oct 27, 5:48PM CDT
RECEPTOS (RCPT), a biotech, reported positive phase 2 trial results for its RPC1063 treatment for ulcerative colitis. Shares shot up 25.1% to 85.02.
RCPT: 109.80 (+0.56)

Receptos lead product successful in Phase 2 for UC at higher dose
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 5:25PM CDT

RCPT: 109.80 (+0.56)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

York Space Systems Faces Class Action Over Misleading IPO

Updated Category News Views 2

York Space Systems Under the Legal Spotlight Ever get that feeling when something just doesn’t sit right? Like a burr under the saddle, York Space Systems is now grappling with a class action lawsuit that's throwing a heap of shade on its recent moves. What’s at play? Bronstein, Gewirtz & Grossman, LLC, a law firm that seems to have a nose for corporate messes, has...

Continue Reading
Hims & Hers Faces Class Action: Investors Beware

Updated Category News Views 1

Allegations and Legal Pressure There's trouble brewing in the land of health and wellness apps, with Hims & Hers Health, Inc. (NYSE:HIMS) taking center stage. Slap on your glasses, folks, because this one's a doozy. A class-action lawsuit has exploded against the company and some of its officers—allegations flying as they focus on serious accusations of misleading...

Continue Reading
ATTACK SHARK Partners with Cloud9 League Team

Updated Category News Views 2

Shaking Hands with Cloud9 ATTACK SHARK is jumping headfirst into the esports game, teaming up with Cloud9's League of Legends team. Now, before you roll your eyes at another corporate matchmaking play, consider the magic at play here. League of Legends isn't just any game; it's a titan in the esports universe, and partnering with Cloud9 offers a serious boost. It's not...

Continue Reading
FDI Launches 'Generation Smile' for Global Oral Health

Updated Category News Views 2

A New Kind of Movement Imagine a campaign not bound by age or geography but united by a shared mission. Generation Smile, freshly launched by the FDI World Dental Federation in Prague, is just that kind of uprising. This initiative redefines existing approaches to oral health, pushing beyond the boundaries of mere dental care to emphasize the integral role oral health...

Continue Reading
Bad Bunny Super Bowl Halftime Show Sweeps 7 Emmy Wins

Updated Category News Views 3

An Unprecedented Performance: A Halftime Show for the Ages Hold onto your hats, folks—Bad Bunny and his Super Bowl LX Halftime Show have taken home a jaw-dropping seven Emmys at the 78th Emmy Awards. This is uncharted territory for any Super Bowl Halftime Show. Never before has a halftime spectacle swept the Emmys like this. We’re talking about categories such as...

Continue Reading
Pudu D7 Robot Shines at IFA, Setting New Robotics Bar

Updated Category News Views 2

Breaking New Ground in Robotics at IFA Well, here's a nugget for robotics buffs and investors alike: Pudu Robotics, a heavyweight in commercial service robotics, is carving out a fresh chapter with its PUDU D7. Making waves as an honoree at the IFA Innovation Awards, the D7 presents a mash-up of brains and brawn—exemplifying the future path for robotics. The PUDU D7...

Continue Reading
EyePoint Stumbles: Legal Eagles Circle Post-Trial Flop

Updated Category News Views 1

EyePoint Slips on Clinical Banana Peel Well, if EyePoint was aiming for a splash, they sure got it—just not the kind they were hoping for. News dropped like a lead balloon when EyePoint announced their Phase 3 DURAVYU trial results for wet age-related macular degeneration, revealing they missed their primary endpoint. And what did that mean for their stock? A death...

Continue Reading
Morpho Unveils Versatile UV Printer at IFA 2026

Updated Category News Views 4

IFA 2026: A New Frontier for Desktop Printing You've seen your fair share of printers over the years, but when a company like Morpho steps onto the scene with a gadget that echoes innovation, it makes you perk up those market-ears. We're talking the big unveil of their desktop UV printer at the IFA 2026 in Berlin. Morpho's contraption isn't just spewing out ink; it's...

Continue Reading
Creality Rolls Out K3, SPARKX i8 at IFA 2026

Updated Category News Views 4

Creality Struts Its Stuff at IFA 2026 You wouldn't guess 3D printing had anything left to dazzle us with, but Creality has sure put those notions to rest at the IFA 2026 in Berlin. They're rolling out the big guns with fresh tech that pushes both efficiency and sustainability—two big buzzwords these days—and ties a neat little bow on their innovative streak....

Continue Reading
Midea's VitaBreeze: Revolutionizing Personalized Climate

Updated Category News Views 2

A Fresh Breeze in Climate Control Here's something that'll shake up your household. Midea just announced their latest gizmo, called VitaBreeze, and they’re not messing around. They introduced it at IFA 2026, promising it's not just for cooling off in the summer or heating in the winter. Oh no, my friends, they've packed this unit with enough cutting-edge tech that...

Continue Reading

Top 5 Most Recently Viewed Articles

Hoyne Bancorp's Transition to Stock Holding Company Explained

Updated Category News Views 240

Hoyne Bancorp, Inc. Announces Conversion Approval Hoyne Bancorp, Inc., a leading financial institution, has recently completed a significant milestone in its evolution. This marks an important phase as the organization transitions from a mutual holding company to a stock holding company, a move that is poised to enhance its operational framework. By transforming into a...

Continue Reading
Incyte's INCB123667 Demonstrates Promise for Ovarian Cancer

Updated Category News Views 133

Incyte's Advancements with INCB123667 Incyte, a forward-thinking biopharmaceutical company known for its innovative therapies, has revealed promising early-stage clinical results for its CDK2 inhibitor, INCB123667. This potential game-changer is designed to target advanced solid tumors, particularly ovarian cancer, where there are still significant unmet medical needs....

Continue Reading
GCL SI Highlights Innovations and Solutions for Solar Energy

Updated Category News Views 167

GCL SI Showcases Innovations at Intersolar Europe At Intersolar Europe 2025, GCL System Integration (GCL SI) presents groundbreaking technologies and comprehensive solar solutions, demonstrating its significant role in photovoltaic advancement. From cutting-edge granular silicon to high-efficiency perovskite modules, GCL is at the forefront of global decarbonization...

Continue Reading
8x8, Inc. Celebrates Inclusion in Newsweek's Excellence Ranking

Updated Category News Views 177

8x8, Inc. Recognized by Newsweek for Corporate Excellence 8x8, Inc. (NASDAQ: EGHT) has recently been acknowledged in the prestigious Excellence 1000 Index published by Newsweek. This esteemed ranking celebrates companies demonstrating outstanding practices in various crucial areas such as financial responsibility and social accountability. Understanding the Excellence...

Continue Reading
James Hardie Industries Faces Leadership Change Amid Lawsuit

Updated Category News Views 183

James Hardie Industries Faces Leadership Turmoil Recently, James Hardie Industries plc (NYSE: JHX) announced a significant leadership transition with the departure of its Chief Financial Officer, Rachel Wilson. Ryan Lada has been brought in as her replacement. This change comes in the wake of troubling developments concerning the company's financial practices and investor...

Continue Reading